Oncolytics Biotech Inc. · NASDAQ:ONCY

Oncolytics Biotech — Investor Presentation (December 2015)

31 slides from Oncolytics Biotech's investor presentation, Dec 7, 2015

  1. Slide 1: Corporate Presentation

    Corporate Presentation December 7, 2015

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains certain forward looking statements relating to the company’s financial results, business prospects and the development and commercialization of REOLYSIN®, a therapeutic reovirus. These statements are based on management’s current expectations and

  3. Slide 3: Oncolytics Overview

    Oncolytics Overview Developing REOLYSIN® 400+ issued patents and (oncolytic virus) as a 235 pending cancer therapeutic applications worldwide Conducted 30+ clinical 1,100+ patients treated; studies in 13 indications strong safety profile Manufacturing $30.56 million total at commercial scale current

  4. Slide 4: What is REOLYSIN?

    What is REOLYSIN®?  Proprietary isolate of the reovirus  Widely found  Non-pathogenic  Widespread human exposure 4

  5. Slide 5: REOLYSIN and Safety

    REOLYSIN® and Safety General Safety  1,100+ patients treated, 1,000+ of these intravenously  No MTD reached  Safety profile confirmed in a randomized setting Monotherapy Safety  Mild toxicities (grade 1 or 2) including • Chills • Cough • Sore throat • Fever • Myalgia • Fatigue • Headache • Runny

  6. Slide 6: REOLYSIN Clinical Program

    REOLYSIN® Clinical Program Indication Studies REO 003 REO 007 REO 008 MAY0 (MC-1472) GLIOMA PhaseI/II PhaseI/II PhaseII NCI (COG-ADVL1014) PhaseI REO 013 Brain PhaseI PhaseI Orphan Status REO 001 REO 002 IND 209 PROSTATE PhaseI PhaseI PhaseII NCI (OSU-07022) NCI (GOG-0186H) OVARIAN PhaseI/II PhaseII

  7. Slide 7: REOLYSIN: Delivery to the Tumour Site

    REOLYSIN®: Delivery to the Tumour Site  When delivered intravenously as a monotherapy, REOLYSIN® has been shown to be delivered to the interior of a tumour in:  Colorectal cancer metastatic lesions to the liver  Brain metastases from various primaries  Primary gliomas and astrocytomas  Ovarian

  8. Slide 8: REOLYSIN: Reducing Tumour Burden

    REOLYSIN®: Reducing Tumour Burden

  9. Slide 9: REOLYSIN Mechanism of Action

    REOLYSIN® Mechanism of Action Normal Cells REOLYSIN® REOLYSIN® REOLYSIN® Healthy cells infects both does not remain tumour cells replicate in undamaged Administer Cellular to patients and normal cells that are stress PRE- healthy cells not Ras event SCREENED activated for RAS, EGFR, BRAF and others

  10. Slide 10: REO 003: Intratumoural Monotherapy Anaplastic Astrocytoma

    REO 003: REOLYSIN® Intratumoural Monotherapy Anaplastic Astrocytoma Early Cytotoxic Activity Followed by Late Stage Immune-Mediated Response Against the Residual Tumour Days after REOLYSIN® administration: 0 3 43 88 167 537 Viral replication mediated Post debulking Immune mediated tumour response tu

  11. Slide 11: REO 021: Partial Response in Squamous Cell Carcinoma of the Lung

    REO 021: Partial Response in Patient with Squamous Cell Carcinoma of the Lung Right Upper Lung Mass (8.3 cm) Right Upper Lung Mass (4.1 cm) Right Upper Lung Mass (3.6 cm) Right Pleural Met (2.2 cm) Right Pleural Met (0.8 cm) Right Pleural Met (0.4 cm) Pre-Treatment Post-Cycle 2 Post-Cycle 4 11

  12. Slide 12: REO 018 Head and Neck Cancer: Randomized Tumour-Specific Response Data

    REO 018 Head and Neck Cancer: Randomized Tumour-Specific Response Data First Endpoint: Velocity Second Endpoint: Volume o 105 patients Loco-regional patients with or without o 86% of test arm (n=50) had distal metastases tumour stabilization or shrinkage o 23% improvement in test arm vs. o 67% of co

  13. Slide 13: REOLYSIN Plus Carfilzomib Response Data in Multiple Myeloma

    REOLYSIN® Plus Carfilzomib Response Data in Multiple Myeloma 0 5 8 4 7 6 3 1 2 Monoclonal Protein -20 % Change of -40 -60 -80 -100 Patients Evaluable for Response Responses evaluated using International Myeloma Working Group (IMWG) Criteria : • Patients 1 & 2 = Very Good Partial Response (VGPR) • Pa

  14. Slide 14: Registration Program for REOLYSIN

    Registration Program for REOLYSIN® Tumour Reduction Endpoints:  Neoadjuvant treatment of muscle-invasive bladder cancer  Neoadjuvant = therapy used prior to a major therapeutic intervention (usually surgery) in order to improve outcome  Muscle invasive bladder cancer is the only cancer indication

  15. Slide 15: REOLYSIN: Improving Overall Survival

    REOLYSIN®: Improving Overall Survival

  16. Slide 16: REOLYSIN Mechanism of Action

    REOLYSIN® Mechanism of Action Normal Cells REOLYSIN® REOLYSIN® REOLYSIN® Healthy cells infects both does not remain Progeny viruses repeat cell tumour cells replicate in undamaged infection cycle in nearby Administer tumour cells Cellular to patients and normal cells that are stress PRE- healthy cel

  17. Slide 17: REO 003: Intratumoural Monotherapy Anaplastic Astrocytoma

    REO 003: REOLYSIN® Intratumoural Monotherapy Anaplastic Astrocytoma Early Cytotoxic Activity Followed by Late Stage Immune-Mediated Response Against the Residual Tumour Days Post Treatment: 0 3 43 88 167 537 Viral replication mediated Post debulking Immune mediated tumour response tumour response 17

  18. Slide 18: Patient Outcomes Are Influenced By Immune Status

    Patient Outcomes Are Influenced By Immune Status  The survival rate of ovarian cancer patients with high PD-L1 expression on entry is statistically significantly worse than that of patients with low PD-L1 expression on entry.  Five year survival was 80.2% for patients with low PD-L1 expression on

  19. Slide 19: REOLYSIN in Multiple Myeloma

    REOLYSIN® in Multiple Myeloma REOLYSIN® + REOLYSIN® + REOLYSIN® REOLYSIN® Carfilzomib, Carfilzomib, Variable Monotherapy, Monotherapy, Statistics Statistics Pre- Post- Pre-Treatment Post-Treatment Treatment Treatment not CD8 58.0 (21.5) 63.9 (18.3) 37.8 (8.5) 84.6 (26.8) p=0.060 significant not PD-L

  20. Slide 20: Top-Line Overall Survival (OS) Results

    Top-Line Overall Survival (OS) Results REO 017 (Pancreatic Cancer) – Comparison with ACCORD 11 and MPACT Studies: CA19.9 ≥20% Median 1-Year 2-Year Median OS Treatment n Decrease from PFS Survival Survival (months) Baseline (months) (%) (%) Gemcitabine (ACCORD 11) 171 N/A 3.3 6.8 20 2 (Conroy et al.,

  21. Slide 21: Top Line Overall Survival (OS) Results

    Top Line Overall Survival (OS) Results REO 016 (Non-Small Cell Lung Cancer) – Comparison with Schiller et al., 2002: 2-Year Median PFS Median OS 1-Year Treatment n Survival (months) (months) Survival (%) (%) Carboplatin and paclitaxel 290 3.1 8.1 34 11 (Schiller et al., 2002) Carboplatin, paclitaxel

  22. Slide 22: Immune Preclinical Research

    Immune Preclinical Research  In ovarian cancer models in mice:  Combination of gemcitabine and reovirus type 3 improved overall survival  In melanoma models in mice:  Combination of GM-CSF with REOLYSIN® improved overall survival  In brain cancer models in mice:  Combination of a checkpoint in

  23. Slide 23: Enhancing Immune Responses to Improve Overall Survival

    Enhancing Immune Responses to Improve Overall Survival  Ongoing preclinical and clinical research has led to three clinical programs: 1. Gemcitabine in combination with REOLYSIN® (REO 009 and REO 017); 2. GM-CSF in combination with REOLYSIN® (Mayo (pediatric) and Leeds (adult)); or 3. Checkpoint in

  24. Slide 24: Registration Program for REOLYSIN

    Registration Program for REOLYSIN® Advanced Gliomas  A key finding from REO 013 was that REOLYSIN® can cross the blood brain barrier and subsequently infect and kill tumour in the brain, as well as primary gliomas and metastatic lesions from other primary cancers outside brain  We have completed a

  25. Slide 25: Manufacturing & Intellectual Property

    Manufacturing & Intellectual Property

  26. Slide 26: Manufacturing

    Manufacturing  Now produced at 100L (commercial scale) under cGMP with final formulation  Commercial manufacturing agreement in place with Sigma- Aldrich® Fine Chemicals (SAFC) 26

  27. Slide 27: Patent Portfolio

    Patent Portfolio  More than 400 patents issued worldwide, including 56 US and 20 Canadian  Reovirus issue patent claims cover: o Compositions of matter comprising reovirus o Pharmaceutical use of reoviruses to treat neoplasia and cellular proliferative diseases o Combination therapy with radiation

  28. Slide 28: Corporate & Financial

    Corporate & | Financial

  29. Slide 29: Market & Capital Data

    Market & Capital Data (all amounts in CAD) Exchanges OTCQX:ONCYF TSX:ONC Shares Outstanding (September 30, 117,963,979 2015) Price Options Outstanding (September 30, $3.16 (weighted 5,531,394 2015) average) Fully Diluted (September 30, 2015) 123,495,373 Total Current Assets (September 30, $30.56 M 2

  30. Slide 30: Investment Highlights

    Investment Highlights  Five ongoing randomized Phase II studies  Ovarian, colorectal, non-small cell lung, prostate and breast cancers  Preparing for registration study and first checkpoint inhibitor study  Safety data for 1,100+ patients  Strong intellectual portfolio  More than 400 patents w

  31. Slide 31: Corporate Presentation

    Corporate Presentation December 7, 2015

Oncolytics Biotech — Investor Presentation (December 2015) on 6ix